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Background: Resistance to apoptosis is a hallmark of cancer and proteins regulating apoptosis have been
proposed as prognostic markers in several malignancies. However, the prognostic impact of apoptotic markers has
not been consistently demonstrated in oral squamous cell carcinoma (OSCC). This inconsistency in reported
associations between apoptotic proteins and prognosis can be partly attributed to the intrinsic low resolution and
misclassification associated with manual, semi-quantitative methods of biomarker expression measurement. The aim
of this study was to examine the association between apoptosis-regulating proteins and clinical outcomes in oral
squamous cell carcinoma (OSCC) using the quantitative fluorescence immunohistochemistry (IHC) based
AQUAnalysis technique.
Methods: Sixty-nine OSCC patients diagnosed between 1998–2005 in Calgary, Alberta, Canada were included in
the study. Clinical data were obtained from the Alberta Cancer Registry and chart review. Tissue microarrays (TMAs)
were assembled from triplicate cores of formalin-fixed paraffin embedded pre-treatment tumour tissue. Bax, Bcl-2
and Bcl-XL protein expression was quantified using fluorescent IHC and AQUA technology in normal oral cavity
squamous epithelium (OCSE) and OSCC tumour samples. Survival was analyzed using Kaplan-Meier plots and the
Cox proportional hazard model.
Results: Bax expression was predominantly nuclear in OCSE and almost exclusively cytoplasmic in OSCC. No similar
differences in localization were observed for Bcl-2 or Bcl-XL. Only Bax expression associated with disease-specific
survival (DSS), with 5-year survival estimates of 85.7% for high Bax versus 50.3% for low Bax (p = 0.006), in univariate
analysis. High Bax expression was also significantly associated with elevated Ki67 expression, indicating that
increased proliferation might lead to an improved response to radiotherapy in patients with elevated Bax
expression. In multivariate analyses, Bax protein expression remained an independent predictor of DSS in OSCC [HR
0.241 (0.078-0.745), p = 0.013].
Conclusions: The AQUA technique used in our study eliminates observer bias and provides reliable and
reproducible estimates for biomarker expression. AQUA also provides essential measures of quality control that
cannot be achieved with manual biomarker scoring techniques. Our results support the use of Bax protein
expression as a prognostic marker in conjunction with other clinico-pathological variables when designing
personalized treatment strategies for OSCC patients.
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Oral cavity squamous cell carcinoma (OSCC) is the most
common form of head and neck squamous cell carcin-
oma (HNSCC). The annual estimated incidence of oral
cancer is almost 300,000 worldwide [1]. OSCC is charac-
terized by significant morbidity and mortality and pre-
sents a considerable challenge to clinical management
due to its high propensity of loco-regional recurrence
and cervical lymph node dissemination. Conventional
multimodal therapy for OSCC is associated with signifi-
cant toxicity and functional impairment. Despite major
advances in diagnostic imaging, surgical reconstruction
and delivery of radiation therapy (RT) and chemother-
apy, the average 5-year survival for OSCC remains close
to 50% [2].
Although several clinical and histopathological and
molecular markers have been proposed [3,4], current
clinical care is directed, primarily, by the tumour-node-
metastasis (TNM) classification system. The TNM sys-
tem describes the attributes of the cancer in terms of the
size and extension of the primary tumour, its nodal in-
volvement and presence of distant metastasis. However,
TMN staging is of limited prognostic value in individual
patients since it does not consider the underlying biol-
ogy of tumour cells. The biological mechanisms that de-
termine the course of OSCC are poorly understood. The
human-papilloma virus (HPV) is a well-known prognos-
tic marker in certain HNSCC subsites such as the
orpharynx, where more than 70% of cases have been
reported to be HPV-positive [5-7]. However, a similar
association between HPV and OSCC has not been estab-
lished [8]. Therefore, novel prognostic and predictive
biomarkers are required to direct optimal management
of OSCC.
Apoptotic pathways are critical cell-autonomous
tumour surveillance mechanisms that guard against the
development of neoplasms. Indeed, evading apoptosis is
considered one of the hallmarks of cancer [9,10]. The
role of mediators of apoptosis has been investigated in
the development and progression of several cancers [11],
including OSCC [12-15]. The evolutionarily conserved B
cell lymphoma-2 (Bcl-2) family of proteins controls
apoptosis by regulating the permeability of the mito-
chondrial outer membrane [16,17]. Members of the Bcl-
2 family are functionally classified as either anti-
apoptotic or pro-apoptotic. Most cells express a variety
of Bcl-2 family proteins and their balance dictates cell
fate [18]. Bcl-2-associated X protein (Bax) [19], is a pro-
apoptotic member of the Bcl-2 family. Bax promotes
mitochondrial outer membrane permeabilization, a hall-
mark of apoptosis, by forming homo-oligomers on the
mitochondrial membrane [20]. Two prominent anti-
apoptotic members of the Bcl-2 family are Bcl-2 and
Bcl-2-related gene long isoform (Bcl-XL) [21]. Theseanti-apoptotic proteins preserve mitochondrial mem-
brane integrity by directly inhibiting the pro-apoptotic
Bcl-2 family members.
Since Bcl-2 and Bcl-XL are anti-apoptotic proteins,
they are expected to function as oncogenes in cancer
cells and pro-apoptotic proteins such as Bax are
expected to act as tumour-suppressors. According to
these assumptions, cancers over-expressing Bcl-2 or Bcl-
XL should have worse prognosis, while tumours over-
expressing Bax should be associated with better clinical
outcomes. However, studies analyzing the prognostic sig-
nificance of apoptotic proteins in OSCC have yielded
contradictory results. Camisasca et al. [22] reported that
the elevated expression of Bax, Bcl-2 and Bcl-XL was
associated with better overall survival, disease-specific
survival (DSS) and lower recurrence rates in OSCC.
Yuen et al. [23] observed no association between Bcl-2
expression and survival in OSCC. Another study
reported associations between increased Bcl-2 expres-
sion, neck metastasis and poor survival, but did not de-
tect any prognostic significance for Bax expression [24].
Other studies have reported improved prognosis in
OSCC patients whose tumours express low levels of Bcl-
2 and high levels of Bax [25,26]. All these studies have
used immunohistochemistry to assess the expression of
the three apoptotic markers, however, no previous stud-
ies have used automated quantitative fluorescent immu-
nohistochemistry [27] to assess the expression levels of
apoptotic proteins in OSCC. Automated quantitative
analysis (AQUA) of tissue microarrays (TMAs) can be
used to measure protein expression, specifically within
tumour cells, on a continuous scale. The technology
serves to remove observer bias and provides essential
standards for quality control that are not available in
conventional immunochemistry analysis techniques in-
volving manual examination of individual TMA cores. In
the present study, we evaluated the expression of Bcl-2,
Bcl-XL and Bax using the AQUA technique in 69 OSCC
tumour samples and compared these results to normal
oral cavity squamous epithelium (OCSE). We also exam-
ined the association of apoptotic biomarker expression
with clinico-pathological variables and DSS in OSCC.
Methods
Cohort identification
Institutional ethics approval was obtained from Conjoint
Health Research Ethics Board at the University of Calgary,
in accordance with the Tri-Council Policy Statement on
Research with Human Subjects. The study cohort con-
sisted of 102 patients with OSCC who were treated with
primary surgery (resection and neck dissection) between
1998 and 2005 at the Foothills Medical Centre, Calgary,
Alberta, Canada (Figure 1). The inclusion criteria for
patients were the histological confirmation of OSCC with
Figure 1 Consort Diagram outlining patient selection criteria for the OSCC study cohort. Sufficient tumour tissue for TMA construction was
available for 69 patients. TMA cores from 64 patients were included in the analysis of Bax expression; TMA cores from 63 patients were analyzed
for Bcl-2 and Bcl-XL expression. The same 63 patients were consistent between Bax, Bcl-2 and Bcl-XL expression analyses. The loss of 5 patients
(Bax expression analysis) and 6 patients (Bcl-2 and Bcl-XL expression analysis) was due to the insufficient tumour, core loss during sectioning, or
folding of the tissue in all three cores of a particular patient.
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Patients received post-operative radiation therapy in any
of 3 situations: 1) metastatic cancer extending beyond the
lymph node capsule 2) multiple metastatic lymph nodes
3) positive surgical margins. Patient demographics and
clinical outcome were collected by a combination of com-
prehensive chart review and data retrieval from the Al-
berta Cancer Registry.
Tissue microarray (TMA) construction
Surgically resected, treatment naïve formalin-fixed, par-
affin–embedded (FFPE) tumour samples were available
for 69 of the 102 patients included in the study and were
retrieved for TMA construction (Figure 1). Hematoxylin
and eosin stained slides obtained from surgical speci-
mens were reviewed by the study pathologist (A.M.) to
confirm the diagnosis. FFPE tumour blocks with sufficient
tumour to obtain three 0.6 mm cores were selected for
each patient and marked for sampling and inclusion into
TMAs. TMAs were assembled from triplicate 0.6 mm
cores randomly sampled from the tumour-containing area
of each FFPE block using a Beecher Manual TissueMicroarrayer (Beecher Instruments Inc. Sun Prairie, WI).
Five samples of normal OCSE, separate from the tumour
containing regions of archived FFPE tissue blocks, were
also included in the TMAs as reference samples to estab-
lish normal biomarker expression levels.
Quantitative fluorescent immunohistochemistry
We used the HistoRxTM AQUA platform and fluores-
cent immunohistochemistry [27] to quantify the expres-
sion of Bcl-2, Bcl-XL, Bax and Ki67 in the tumour
compartment of each TMA core. TMA sections (4 μm)
were deparaffinized in xylene, rinsed in ethanol, and
rehydrated. Heat induced epitope retrieval for Ki67 was
performed by heating slides to 121 °C in a citrate-based
Target Retrieval Solution (pH 6.0) (Dako) for 6 minutes
in a decloaking chamber (Biocare Medical). For Bcl-2,
Bcl-XL and Bax, an EDTA-containing Target Retrieval
Solution (pH 9.0) (Dako) was used for 3 minutes. TMA
slides were stained for Bcl-2 (rabbit monoclonal anti-
Bcl-2, 1:1000 dilution, Epitomics), Bcl-XL (rabbit mono-
clonal anti-Bcl-XL, 1:500 dilution, Cell Signaling), Bax
(rabbit monoclonal anti-Bax, 1:5000 dilution, Epitomics)
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Dako). Rabbit Envision + or mouse Envision + (Dako)
was used in conjunction with tyramide-Cy3 (Perkin-
Elmer) for Ki67 or tyramide-Cy5 (Perkin-Elmer) for the
Bcl-2 family members to visualize the expression level of
each biomarker. The epithelial (tumour) compartment
was identified by staining with a guinea-pig anti-pan-
cytokeratin (PCK) antibody (ACRIS) and an Alexa488
conjugated anti-guinea pig secondary antibody. Slides
were mounted using Prolong Gold Anti-fade with DAPI
(Invitrogen). Slides were scanned by HistoRx PM-2000™
and analyzed by AQUAnalysisW software (version 2.2.1.7).
The tumour compartment was defined as the PCK-positive
area for each TMA core, the tumour nuclear compartment
was defined as the DAPI-positive area within the tumour
compartment, and the Ki67 compartment area was defined
as the Ki67 positive area within the tumour nuclear com-
partment. Unusable areas within each image (such as those
with folded tissue) where manually cropped. Also, cores
with insufficient tumour area (<20% tumour) were
excluded from further analysis. AQUAnalysisW software
was used to calculate AQUA scores representing the
exposure time-adjusted pixel intensity density of bio-
marker proteins within the tumour compartment area
of each core. Ki67 expression was reported as the per-
centage of tumour nuclear area that was positive for
Ki67. Expression of a given biomarker was also deter-
mined in normal OCSE.
Statistical Analysis
The distribution of AQUA scores was assessed with re-
spect to normal oral cavity squamous epithelium to de-
termine the relative expression level of each biomarker
in tumour tissue. The median tumour AQUA score for
each biomarker was selected to dichotomize patients
into low or high expression groups for each biomarker.
A biomarker was defined to be overexpressed in tumour
tissue if the median AQUA score in the tumour
exceeded the median AQUA score in normal OCSE.
The Fisher's exact test was used to compare patient
characteristics between the two patient groups defined
by low/high Bax, Bcl-2 and Bcl-XL expression. Kaplan-
Meier survival analysis was used to assess 5-year DSS.
Survival was measured from the date of diagnosis to the
date of death or the date of last follow-up. Cox propor-
tional hazards analyses were conducted to assess the
impact of clinical covariates. Pathological T-stage and N-
stage were included in the multivariate analysis because
of their clinical significance and their significant associ-
ation with DSS in univariate analysis (Table 1). The stage
covariate was not included in the Cox model because it
is collinear with T-stage and N-stage. All statistical ana-
lyses were performed using Stata 11 data analysis and
statistical software (StataCorp LP, Tx, USA).Results
Cohort characteristics
Our study, adheres to the REMARK criteria [28]. Sixty-
nine patients met the inclusion criteria for the study and
had FFPE tissue available for TMA construction. Median
follow-up time for the cohort was 44 months. Univariate
analyses of potentially relevant clinico-pathological char-
acteristics are presented in Table 1. Stratified analyses
according to low/high Bax, Bcl-2 and Bcl-XL are also
presented in Table 1. The study cohort consisted of 49
males and 20 females (median age 62.6 years, range
25.7-83.3 years). Our cohort contained both low (pT1/
pT2; n = 38) and high (pT3/pT4; n = 31) pathologic
T-stages. Nodal involvement (pN1/pN2) was present in
30 patients. Twenty six of the 69 patients were classified
as clinical stage I/II, and 43 were classified as clinical
stage III/IV. Treatment consisted of surgery alone or
surgery followed by RT for 18 and 51 patients, respect-
ively. The 5 year disease-specific survival for the cohort
was 72%.
Bax protein expression
We observed weak, predominantly nuclear expression of
Bax in OCSE; expression was most prominent in the
basal epithelial layer. In contrast, Bax expression in
OSCC samples was distinctly cytoplasmic and ranged
from sporadic expression in low expressing tumours to
ubiquitous expression in high expressing tumours
(Figure 2A). The median Bax AQUA score in normal
OCSE was 2650 [95%C.I. 937–4362] (Figure 2B, broken
blue lines). Median Bax expression in the OSCC tumour
samples was 5015 [95%C.I. 4458–5483]; this exceeded
the 95%C.I. of Bax expression in normal OCSE and con-
sequently, met our definition of over-expression. Bax
over-expression within the tumour was significantly
associated with a high proliferation index (p = 0.001)
determined by greater than median nuclear Ki67 expres-
sion (Table 1).
Bcl-2 protein expression
The typical Bcl-2 staining pattern in normal OCSE was
weakly cytoplasmic with a slightly increased level of ex-
pression in the basal epithelial layer (Figure 3A). Bcl-2
expression in OSCC samples was also cytoplasmic and
ranged from diffuse expression in low-expressing tumours
to strong sporadic expression in high-expressing tumours
(Figure 3A). The median Bcl-2 AQUA score in normal
OCSE was 807 [95%C.I. 427–1187] (Figure 3B, broken
blue lines). Median Bcl-2 expression in OSCC was 783
[95%C.I. 718–830], which overlapped with the median ex-
pression of Bcl-2 in OCSE (Figure 3B). Significantly more
patients with high Bcl-2 expressing tumours (greater than
median) were treated with RT in addition to surgery
(p= 0.011) (Table 1).
Table 1 Association of demographic and clinico-pathological characteristics with expression levels of Bax, Bcl-2 and
Bcl-XL





95% CI p-value Low High p-value Low High p-value Low High p-value
GENDER 1.72 0.693 - 4.286 0.24 0.419 0.109 0.419
Male 49 71.01 20 24 18 25 20 23
Female 20 28.99 12 8 13 7 12 8
AGEb 1.35 0.543 - 3.364 0.52 1.000 0.315 0.616
<60 years 29 42.03 15 14 12 17 16 13
≥60 years 40 57.97 17 18 19 15 16 18
pT STATUS 2.55 1.022 - 6.357 0.05 0.616 0.207 0.616
1 + 2 38 55.07 19 16 20 15 19 16
3 + 4 31 44.93 13 16 11 17 13 15
pN STATUS 7.470 2.467 -
22.611
<0.0001 0.315 0.802 1.000
N0 39 56.52 15 20 16 18 17 17
N1 + N2 30 43.48 17 12 15 14 15 14
SMOKING
HISTORY
0.65 0.245 - 1.702 0.38 0.075 0.148 0.237
Never 15 21.74 11 4 10 5 10 5
Ever 54 78.26 21 28 21 27 22 26
ALCOHOL
HISTORY
0.46 0.162 - 1.282 0.14 1.000 1.000 1.000
Never 11 17.46 5 4 4 5 5 4
Ever 52 82.54 27 23 23 26 24 24
TUMOUR
DIFFERENTIATION
1.62 0.772 - 3.427 0.2 1.000 0.923 0.525
Well 14 22.95 7 6 6 7 8 5
Moderate 38 62.30 18 18 19 16 15 20
Poor 9 14.75 4 3 4 3 3 4
TREATMENT 2.16 0.629 - 7.412 0.22 0.257 0.011 0.164
Surgery 18 26.09 6 11 13 4 6 11
Surgery + RXT 51 73.91 26 21 18 28 26 20
STAGE 4.68 1.358 -
16.087
0.01 1.000 0.797 1.000
I + II 26 37.68 11 12 12 11 12 11
III + IV 43 62.32 21 20 19 21 20 20
PROLIFERATION
(Ki67)
0.6 0.231 - 1.539 0.29 0.001 0.617 0.211
Low 32 50.00 23 9 17 15 19 13
High 32 50.00 9 23 14 17 13 18
aCut-point selected at median.
bMedian value.
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Both nuclear and cytoplasmic Bcl-XL staining was
observed in normal OCSE, with consistently stronger
staining in the cytoplasm. Bcl-XL was strongly expressed
in all OSCC samples and, similar to OCSE, exhibited a
strong cytoplasmic and weak nuclear staining pattern
(Figure 4A). The median Bcl-XL AQUA score in normalOCSE was 2480 [95%C.I. 1305–3655] (Figure 4B,
broken blue lines). Median Bcl-XL expression in the
OSCC tumour samples was 3450 [95%C.I. 3248–3705]
which approached the upper limit of Bcl-XL expression
in normal OCSE 95%C.I.; we defined this as borderline
overexpression. High Bcl-XL expression was not asso-
ciated with any clinico-pathologic variables (Table 1).
Figure 2 Fluorescent immuno-histochemical staining of Bax using the HistoRxTM AQUA platform. (A) Representative examples of
quantitative fluorescent IHC images for Bax expression in normal OCSE (top panel) and OSCC (two bottom panels). AQUA scores represent the
expression level of Bax within the pan-cytokeratin defined epithelial/tumour compartment. DAPI-stained nuclei are depicted in blue, pan-cytokeratin-
stained epithelial/tumour cells are depicted in green, and Bax protein expression is depicted in red. (B) Histogram distribution representing Bax
expression within OSCC tumour samples. The solid blue line represents median Bax expression in normal OCSE, the broken blue lines represent
+/−2 standard deviations from median Bax expression in normal OCSE, and the solid red line represents median Bax expression in OSCC.
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High Bax expression was associated with significantly
improved 5-year DSS (Figure 5A). The survival estimates
for patients with high and low Bax-expressing tumours
were 85.7% and 50.3%, respectively. High Bax expression
was also associated with a high proliferation index (as
measured by greater than median Ki67 expression)
(p = 0.001, Table 1). Although not statistically significant,
we observed a positive correlation between Ki67 expres-
sion and DSS (Additional file1: Figure S1). Neither Bcl-2
nor Bcl-XL expression levels were associated with DSS
(Figures 5B and 5C). Since the Bcl-2/Bax ratio and theBcl-XL/Bax ratio has been shown to associate with sur-
vival outcomes in OSCC and other cancers [26], we
examined if a similar association existed in our OSCC co-
hort using automated quantitative IHC analysis. We did
not observe a significant association between these ratios
and DSS in our study (Additional file 2: Figure S2).
A Cox proportional hazards model was used to assess
the independent prognostic value of Bax, the only bio-
marker that reached statistical significance in univariate
analysis. Lymph node status (negative/positive) and
pathologic T-stage (T1/T2 vs. T3/T4) were included
with Bax (high/low) in the multivariate model since
Figure 3 Fluorescent immuno-histochemical staining of Bcl-2 using the HistoRxTM AQUA platform: (A) Representative examples of
quantitative fluorescent IHC images for Bcl-2 expression in normal OCSE (top panel) and OSCC (two bottom panels). AQUA scores represent the
expression level of Bcl-2 within the pan-cytokeratin defined epithelial/tumour compartment. DAPI-stained nuclei are depicted in blue, pan-
cytokeratin-stained epithelial/tumour cells are depicted in green, and Bcl-2 protein expression is depicted in red. (B) Histogram distribution
representing Bcl-2 expression within OSCC tumour samples. The solid blue line represents median Bcl-2 expression in normal OCSE, the broken
blue lines represent +/−2 standard deviations from median Bcl-2 expression in normal OCSE, and the solid red line represents median Bcl-2
expression in OSCC.
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making treatment decisions. All three variables, Bax [HR
0.236 (0.076-0.731), p = 0.012], lymph node status [HR
7.344 (2.090-25.803), p = 0.002] and pathologic T-stage
[HR 3.261 (1.234-8.618), p = 0.017], were significantly
and independently associated with DSS (Table 2).
Discussion
The current prediction of prognosis in OSCC is based
primarily on the TNM staging system and does notconsider the contribution of molecular biomarkers or
underlying tumour biology when assigning stage or pre-
dicting outcomes. This may be attributed to the lack of
robust and reliable techniques for measuring biomarker
expression that will help validate their use in the clinic.
Several studies have investigated whether changes in the
expression levels of apoptosis-associated proteins are
associated with survival outcomes in OSCC [14,22,29,30].
However, a lack of consensus in these studies has
precluded the use of apoptotic protein expression as
Figure 4 Fluorescent immuno-histochemical staining of Bcl-XL using the HistoRxTM AQUA platform. (A) Representative examples of
quantitative fluorescent IHC images for Bcl-XL expression on normal OCSE (top panel) and OSCC (two bottom panels). AQUA scores represent the
expression level of Bcl-XL within the pan-cytokeratin defined epithelial/tumour compartment. DAPI-stained nuclei are depicted in blue, pan-
cytokeratin-stained epithelial/tumour cells are depicted in green, and Bcl-XL protein expression is depicted in red. (B) Histogram distribution
representing Bcl-XL expression within OSCC tumour samples. The solid blue line represents median Bcl-XL expression in normal OCSE, the broken
blue lines represent +/−2 standard deviations from median Bcl-XL expression in normal OCSE, and the solid red line represents median Bcl-XL
expression in OSCC.
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based techniques, such as AQUA, can be used to
eliminate observer bias in the measurement of protein
expression. Furthermore, AQUA can measure protein ex-
pression within distinct sub-cellular and tissue compart-
ments (e.g. defining expression in the nucleus/cytoplasm
and tumour/stroma), possibly improving the clinical ap-
plicability of this technique. In the present study, we
measured the expression of three apoptosis-regulating
proteins using AQUA and found that Bax expression was
an independent prognostic marker in OSCC.Several reports suggest that Bax plays a tumour sup-
pressor role in human malignancies and high Bax ex-
pression is associated with favourable prognosis in
several cancer types [31-35]. Our univariate analysis
showed that high Bax expression is associated with
improved prognosis. Furthermore, multivariate analysis
using Cox proportional hazards regression to adjust for
important clinical covariates, confirmed that Bax expres-
sion was independently associated with DSS in OSCC.
Tumours with high Bax expression are likely to be more
susceptible to apoptosis than their low Bax-expressing
Figure 5 Kaplan-Meier survival analysis of Bax, Bcl-2 and Bcl-XL expression. Kaplan-Meier survival curves and corresponding risk tables for
5 year disease-specific survival in OSCC patients with below median or above median (A) Bax, (B) Bcl-2, and (C) Bcl-XL.
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expression is selectively induced in apoptosis-proficient
cells [36]; therefore, OSCC cells with elevated Bax ex-
pression could be those that are primed for apoptosis
due to the inherent genetic instability associated with
malignant transformation.
High Bax expression was associated with increased
Ki67 expression, a marker of proliferation. This is con-
sistent with previously reported associations between
Bax expression and proliferation in several cancer sites
[37,38]. Bax over-expression increases cellular prolifera-
tion and accelerates G1 to S-phase transition [39,40]; this
increased cellular proliferation in genetically unstable
cancer cells can lead to mitotic catastrophe, thereby aug-
menting cell death induced by apoptosis in response to
radiotherapy [41]. The increased proliferation associated
with elevated Bax expression could confer an improvedTable 2 Univariate and multivariate (Cox proportional hazard
Univariate
Hazard Ratio (95%C.I.) p-va
Bax 0.237 (0.078 - 0.721) 0.005
pT Status 2.549 (1.022 - 6.357) 0.043
pN Status 7.470 (2.467 - 22.611) <0.0
Pathological T-stage and N-stage were included in the multivariate analysis based o
association with DSS in univariate analysis.response to radiotherapy in patients with high Bax. In-
deed, stratification by radiation treatment demonstrated
that the association between Bax expression and DSS
was most pronounced in patients that received adjuvant
radiotherapy (Additional file 3: Figure S3); however, we
were unable to appropriately assess this effect in our co-
hort. Although not statistically significant, a weak associ-
ation was observed between high Ki67 expression and
improved 5-year DSS (Additional file 1: Figure S1).
Since the increased expression of Bcl-2 and Bcl-XL
proteins are integral to the survival of malignant cells, it
was not surprising that we did not observe any associ-
ation between the expression of these proteins and 5-
year DSS. In effect most tumours rely on the increased
expression of antiapoptotic proteins and therefore these
proteins will not likely identify unique patient subsets
with regard to outcome. We also investigated if thes) analysis of 5-year disease-specific survival
Multivariate
lue Hazard Ratio (95%C.I.) p-value
0.236 (0.076 - 0.731) 0.012
3.261 (1.234 - 8.618) 0.017
01 7.344 (2.090 - 25.803) 0.002
n their acknowledged clinical significance in OSCC and their significant
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teins was associated with DSS by testing the impact of
Bcl-2/Bax and Bcl-XL/Bax ratios on survival outcome.
However, we did not find any significant association be-
tween these ratios and 5-year DSS. A possible explan-
ation might be the altered expression of additional
apoptosis-regulating factors that determine cell fate [30].
We evaluated the cellular localization of the three
apoptosis-associated proteins in our study and found
that Bax expression was predominantly nuclear in nor-
mal OCSE but primarily cytoplasmic in OSCC. Previous
studies have also reported the presence of Bax and Bcl-2
in the nucleus [42-44], however the function of nuclear
Bax in our study remains unclear. The sub-cellular
localization of Bcl-2 and Bcl-XL was similar in normal
and tumour tissue. Bax was the only biomarker that
exhibited a difference in sub-cellular localization be-
tween normal OCSE and OSCC and was also the only
apoptotic protein significantly associated with prognosis.
The translocation of Bax from the nucleus to the cyto-
plasm in OSCC is consistent with increased Bax func-
tion at the mitochondria, leading to improved sensitivity
to radiotherapy-induced apoptosis in tumours with ele-
vated Bax expression.
Bax and Bcl-XL were over-expressed in most tumour
samples, while a majority of the tumour samples
expressed Bcl-2 at levels equivalent to normal OCSE.
These results suggest that Bcl-XL might be the major
anti-apoptotic protein in oral carcinogenesis and the
increased Bax expression may be a compensatory re-
sponse to elevated Bcl-XL levels. Interestingly, we
observed that patients treated with surgery alone were
over-represented in the low Bcl-2 group, whereas
patients additionally treated with post-surgery RT were
more common in the high Bcl-2 group (Table 1). How-
ever, since Bcl-2 did not correlate with treatment out-
come, this observation may be attributed to chance
rather than a true biologic phenomenon.
A major strength of our study is the use of automated
quantitative immunohistochemistry to quantify biomarker
expression. The high-throughput technique eliminates
observer bias and provides reliable and reproducible esti-
mates for biomarker expression. We used normal tissue
samples to obtain physiologically relevant estimates of
biomarker expression and define over-expression or
down-regulation of apoptotic biomarker in our OSCC
cohort. Our study included samples from a single head
and neck sub-site (oral cavity) and a uniformly treated
cohort from a single cancer center, thus minimizing treat-
ment heterogeneity and increasing the reliability of our
results.
Our study is limited by its relatively small sample size
and retrospective nature. Despite the advantages of the
AQUA technique for discovery-phase studies, it is notwidely available in routine laboratory diagnostics at
present, limiting its current clinical utility. However, the
robustness and reliability of AQUA makes it amenable
for adoption as a routine tool for prognostication in the
imminent future.
Conclusions
High Bax expression could serve to stratify OSCC
patients with better prognosis, in a manner similar to
HPV status in cancers of the oropharynx. Since both
chemotherapy and radiotherapy work by inducing apop-
tosis in rapidly proliferating cells, our results suggest
that combined modality treatments should be explored
in patients with low Bax and Ki67-expressing tumours
[45]. Confirmation of the prognostic significance of Bax
expression in OSCC in prospective studies could trans-
late into a simple immuno-histochemical test that might
be useful for treatment selection and prognostication.
Such an approach could lead to personalized approaches
in treating this challenging disease.
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for patients treated with surgery only (no radiation). Cut-points were
selected at median.
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